How to overcome the side effects of tumor immunotherapy

Li, Shang; Zhang, Zhi-Bi; Lai, Wing‐Fu; Cui, Liao; Zhu, Xiao

doi:10.1016/j.biopha.2020.110639

Cited by 47 publications

(24 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the incidence of these two kinds of hematological malignancies is increasing year by year, which undoubtedly poses a serious threat to human health and life safety. The occurrence and development of hematological malignancies are very rapid and complex, which is a complex process of the interaction between internal genetic factors (38)(39)(40)(41)(42)(43)(44), molecular signal transduction (45,46), metabolic factors (47)(48)(49), immune factors (50)(51)(52)(53)(54)(55), and tumor microenvironment (41,(56)(57)(58)(59). Although current chemotherapy can prolong the survival time of tumor patients (60,61), the prognosis and economic burden are still difficult problems in clinical work.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is one of the most active modification factors of mRNA, which is closely related to cell proliferation, differentiation, and tumor development. Here, we explored the relationship between the pathogenesis of hematological malignancies and the clinicopathologic parameters. The datasets of hematological malignancies and controls were obtained from the TCGA [AML (n = 200), DLBCL (n = 48)] and GTEx [whole blood (n = 337), blood vascular artery (n = 606)]. We analyzed the m6A factor expression differences in normal tissue and tumor tissue and their correlations, clustered the express obvious clinical tumor subtypes, determined the tumor risk score, established Cox regression model, performed univariate and multivariate analysis on all datasets. We found that the AML patients with high expression of IGF2BP3, ALKBH5, and IGF2BP2 had poor survival, while the DLBCL patients with high expression of METTL14 had poor survival. In addition, “Total” datasets analysis revealed that IGF2BP1, ALKBH5, IGF2BP2, RBM15, METTL3, and ZNF217 were potential oncogenes for hematologic system tumors. Collectively, the expressions of some m6A regulators are closely related to the occurrence and development of hematologic system tumors, and the intervention of specific regulatory factors may lead to a breakthrough in the treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Generally, the higher the mutation load, the higher the possibility of producing MHC-bond peptides. Inhibitory immune cells (such as tumorassociated macrophages) and tumor-causing inflammatory mediators (such as TNF-a、 IL-6、 TGF-b) in tumor microenvironment can stimulate tumor cell proliferation and induce tumor angiogenesis by inhibiting NF-kB and STAT3 signaling pathways, promote the tumor immune escape as well as the tumor invasion and metastasis (45)(46)(47).…”

Section: Checkpoint Inhibitormentioning

confidence: 99%

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Zhu

2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy is a kind of therapy that can control and eliminate tumors by restarting and maintaining the tumor-immune cycle and restoring the body’s normal anti-tumor immune response. Although immunotherapy has great potential, it is currently only applicable to patients with certain types of tumors, such as melanoma, lung cancer, and cancer with high mutation load and microsatellite instability, and even in these types of tumors, immunotherapy is not effective for all patients. In order to enhance the effectiveness of tumor immunotherapy, this article reviews the research progress of tumor microenvironment immunotherapy, and studies the mechanism of stimulating and mobilizing immune system to enhance anti-tumor immunity. In this review, we focused on immunotherapy against tumor microenvironment (TME) and discussed the important research progress. TME is the environment for the survival and development of tumor cells, which is composed of cell components and non-cell components; immunotherapy for TME by stimulating or mobilizing the immune system of the body, enhancing the anti-tumor immunity. The checkpoint inhibitors can effectively block the inhibitory immunoregulation, indirectly strengthen the anti-tumor immune response and improve the effect of immunotherapy. We also found the checkpoint inhibitors have brought great changes to the treatment model of advanced tumors, but the clinical treatment results show great individual differences. Based on the close attention to the future development trend of immunotherapy, this study summarized the latest progress of immunotherapy and pointed out a new direction. To study the mechanism of stimulating and mobilizing the immune system to enhance anti-tumor immunity can provide new opportunities for cancer treatment, expand the clinical application scope and effective population of cancer immunotherapy, and improve the survival rate of cancer patients.

show abstract

“…In terms of treatment, tumor-targeted drug delivery has the potential to improve therapeutic efficacy and reduce the non-specific toxicity of anti-cancer drugs [84][85][86][87]. BM-MSCs have been shown to migrate specifically to inflammatory sites, including tumors, and are expected to serve as tumor-specific carriers to deliver antineoplastic drugs.…”

Section: Applications Of Mscs In Cancermentioning

confidence: 99%

Mesenchymal stem cells: ideal seeds for treating diseases

Gao

Fan

et al. 2021

Human Cell

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), a kind of multipotent stem cells with self-renewal ability and multi-differentiation ability, have become the "practical stem cells" for the treatment of diseases. MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn's disease. MSCs also can be used in cancer and aging. At present, many clinical experiments are using MSCs. MSCs can reduce the occurrence of inflammation and apoptosis of tissue cells, and promote the proliferation of endogenous tissue and organ cells, so as to achieve the effect of repairing tissue and organs. MSCs presumably also play an important role in Corona Virus Disease 2019 (COVID-19) infection. Keywords Mesenchymal stem cells • Autoimmune diseases • Aging • Inflammation • Cancer • COVID-19 Abbreviations AA Alginate ARDS Acute respiratory distress syndrome BM-MSCs Bone marrow mesenchymal stem cells BMP-2 Bone morphogenetic protein 2 CBX4 Chromobox protein homologue 4 CRISPR Clustered Regularly Interspaced Short Palindromic Repeats Cas9 CRISPR-associated protein-9 nuclease Col Collagen COPD Chronic obstructive pulmonary disease COVID-19 Corona Virus Disease 2019 CRC Colorectal cancer CXCR7 C-X-C chemokine receptor type 7 CXCL12 C-X-C motif chemokine ligand 12

show abstract

How to overcome the side effects of tumor immunotherapy

Cited by 47 publications

References 65 publications

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Mesenchymal stem cells: ideal seeds for treating diseases

Contact Info

Product

Resources

About